About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
As clinical oncologists gathered in Chicago to meet at the American Society of Clinical Oncology (ASCO)’s Annual Meeting, PhRMA held a media briefing to discuss critical issues facing the future of cancer research and treatment.
Reporters heard from Stephen J. Ubl, President and CEO of PhRMA, alongside industry and patient advocacy leaders on impacts the Inflation Reduction Act (IRA) will have on the research and development (R&D) of cancer treatments. The group also shared the results of a new analysis from the Partnership for Health Analytics and Research (PHAR) on how price setting provisions in the IRA impact R&D for cancer medicines.
When:
June 2, 2023 in Chicago, IL
Speakers:
- Stephen J. Ubl, President and CEO, PhRMA
- Vas Narasimhan, CEO, Novartis; Board Chair, PhRMA
- Alexander Hardy, CEO, Genentech
- Jeff Allen, President and CEO, Friends of Cancer Research
Event
Economic Impact
PhRMA’s Media Briefing at ASCO
PhRMA’s Media Briefing at ASCO image